Next Post

As amyloid-targeting therapies for Alzheimer's fail, where might success lie? (NYSE:LLY)

[ad_1] tupungato/iStock through Getty Pictures Mid- and late-stage facts readouts about the very last number of many years for Alzheimer’s therapies have experienced a similar theme: Failure. Just about all these candidates have a person detail in frequent: They target lowering beta-amyloid plaque in the brain that is thought to […]